- $2.37bn
- $1.64bn
- $630.20m
- 43
- 26
- 48
- 33
REG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Full Approval for ORPATHYS in China
AnnouncementRCS - Hutchmed China Ltd - China NDA Acceptance for ORPATHYS and TAGRISSO
AnnouncementREG - Hutchmed China Ltd - US$608m Divestment of Non-Core Joint Venture
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Appointment of Joint Corporate Broker
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Receive Milestone Payment from Takeda
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation in China
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce ELUNATE Approval
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Continued Inclusion of ORPATHYS in China NRDL
AnnouncementRCS - Hutchmed China Ltd - FRUZAQLA® Launched in Japan by Takeda
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Clinical Data to be Presented at ASH and ESMO Asia
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - First Commercial Milestone Payment
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementREG - Hutchmed China Ltd - SAVANNAH: clinically meaningful response rate
Announcement